- 1 Title: Analysis of severe illness after post-vaccination COVID-19 breakthrough among adults with and
- 2 without HIV in the United States
- 3

4	Authors: Raynell Lang, MD MSc ^{1,2} , Elizabeth Humes, MPH ¹ , Sally B. Coburn, PhD MPH ¹ , Michael A.
5	Horberg, MD, MAS ³ , Lily F Fathi, MPH ³ , Eric Watson, BA ³ , Celeena R Jefferson, MIT ³ , Lesley S. Park, PhD,
6	MPH ⁴ , Amy C. Justice, MD, PhD ^{5,6,7} , Kirsha S. Gordon, PhD, MS ^{6,7} , Kathleen M Akgün, MD MS ^{6,7} , Sonia
7	Napravnik, PhD ^{8,9} , Jessie K. Edwards, PhD, MSPH ⁸ , Lindsay E. Browne, BA ⁹ , Deana M. Agil, MR ⁹ , Michael
8	J. Silverberg, PhD, MPH ¹⁰ , Jacek Skarbinski MD ^{10,11} , Wendy A. Leyden, MPH ¹⁰ , Cameron Stewart, MS ¹ ,
9	Brenna C Hogan, MPH ¹ , Kelly A. Gebo, MD, MPH ^{1,12} , Vincent C. Marconi ^{13,14} , Carolyn F. Williams, PhD ¹⁵ ,
10	and Keri N. Althoff, PhD MPH ¹ for the Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-
11	ACCORD of leDEA
12	
13	1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
14	2. Department of Medicine, University of Calgary, Calgary, Canada
15	3. Kaiser Permanente Mid-Atlantic States, Mid- Atlantic Permanente Research Institute, Rockville, MD,
16	USA
17	4. Stanford Center for Population Health Sciences, Palo Alto, CA, USA
18	5. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA
19	6. Department of Medicine, Yale School of Medicine, New Haven, CT, USA
20	7. VA Connecticut Healthcare System, West Haven, CT, USA
21	8. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
22	9. Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill,
23	NC, USA
24	10. Kaiser Permanente Northern California, Division of Research, Oakland CA, USA
25	11. Department of Infectious Diseases, Oakland Medical Center, Oakland CA, USA
26	12. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
27	13. Emory University School of Medicine and Rollins School of Public Health, Atlanta, GA, USA
	1

	medRxiv preprint doi: https://doi.org/10.1101/2022.04.15.22273913; this version posted April 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
28	14. Atlanta Veterans Affairs Medical Center, Decatur, GA, USA
29	15. Epidemiology Branch, Division of AIDS at National Institute of Allergy and Infectious Diseases
30	(NIAID), National Institute of Health (NIH), Rockville, MD, USA
31	
32	Corresponding author:
33 34 35 36 37 38 39 40	Keri N Althoff, PhD, MPH Associate Professor Department of Epidemiology Johns Hopkins Bloomberg School of Public Health 615 N Wolfe St, Rm E7142 Baltimore, MD 20295 kalthoff@jh.edu
41	Keywords: HIV, COVID-19, SARS-CoV-2, vaccination, breakthrough, hospitalization, severe illness
42 43 44 45	Key Points:
46	Question: In 2021, among fully vaccinated people with COVID-19 breakthrough illness, was the risk of
47	severe illness higher in people with HIV (PWH) compared to people without HIV (PWoH)?
48	
49	Findings: PWH with <350 cells/mm ³ have a 59% increased risk of severe breakthrough illness compared to
50	PWoH.
51	
52	Meaning: Vaccinations effectively reduce the risk of severe COVID-19 infection in both PWH and PWoH;
53	however, PWH having a CD4 count <350 cells/mm ³ are at higher risk of severe breakthrough infection
54	compared to PWoH. PWH with moderate immune suppression should be considered for additional vaccine

55 dosages and other risk-reduction measures.

56 ABSTRACT

- 57 Importance: Understanding the severity of post-vaccination COVID-19 breakthrough illness among people
- with HIV (PWH) can inform vaccine guidelines and risk-reduction recommendations.
- 59
- 60 **Objective:** Estimate the rate and risk of severe breakthrough illness among vaccinated PWH and people
- 61 without HIV (PWoH) who experience a breakthrough infection.
- 62
- 63 **Design, setting, and participants:** The Corona-Infectious-Virus Epidemiology Team (CIVET-II)
- 64 collaboration consists of four US longitudinal cohorts from integrated health systems and academic centers.
- Adults (≥18 years old), in-care, fully vaccinated by June 30, 2021 with HIV, and matched PWoH (on date fully
- 66 vaccinated, age group, race/ethnicity, and sex) were the source population. Those who experienced a post-
- 67 vaccination SARS-CoV-2 breakthrough infection were eligible. Severe COVID-19 breakthrough illness was
- defined as hospitalization due to COVID-19. Discrete time proportional hazards models estimated adjusted
- 69 hazard ratios (aHR) and 95% confidence intervals ([,]) of severe breakthrough illness by HIV status adjusting
- for demographics, COVID-19 vaccine type, and clinical factors. The proportion of patients requiring
- 71 mechanical ventilation or died was compared by HIV status.
- 72
- 73 **Exposure:** HIV infection
- 74

Outcome: Severe COVID-19 breakthrough illness, defined as hospitalization within 28 days after a
 breakthrough SARS-CoV-2 infection with a primary or secondary COVID-19 discharge diagnosis.

- 77
- 78 **Results:** Among 1,241 PWH and 2,408 PWoH with breakthrough infections, the cumulative incidence of
- revere illness in the first 28 days was low and comparable between PWoH and PWH (7.3% vs. 6.7%,
- respectively, risk difference=-0.67% [-2.58%, 1.23%]). The risk of severe breakthrough illness was 59%
- higher in PWH with CD4 counts <350 cells/mm³ compared with PWoH (aHR=1.59 [0.99, 2.46]). In
- 82 multivariable analyses among PWH, being female, older, having a cancer diagnosis, and lower CD4 count

- 83 increased the risk of severe breakthrough illness, while previous COVID-19 reduced the risk. Among all
- 84 patients, 10% were mechanically ventilated and 8% died, with no difference by HIV status.
- 85
- 86 **Conclusions and Relevance:** The risk of severe COVID-19 breakthrough illness within 28 days of a
- 87 breakthrough infection was low among vaccinated PWH and PWoH. However, PWH with moderate and
- 88 severe immune suppression had a higher risk of severe breakthrough infection. Recommendations for
- 89 additional vaccine doses and risk-reduction strategies for PWH with moderate immune suppression may be
- 90 warranted.

91 INTRODUCTION

92	SARS-CoV-2 vaccination is an effective protective measure against coronavirus disease 2019
93	(COVID-19). ¹⁻³ Although uncommon, people with HIV (PWH) have a higher risk for post-vaccination (i.e.
94	breakthrough) SARS-CoV-2 infection. ⁴⁻⁹ Our prior study showed a 28% increased risk for breakthrough
95	SARS-CoV-2 infection in PWH compared to people without HIV (PWoH), although breakthrough cumulative
96	incidence was low (PWH=3.1%, PWoH=2.5%), consistent with findings among people with other
97	immunosuppressive conditions. ^{4,5,9} Data on breakthrough COVID-19 illness, particularly severe illness
98	requiring hospitalization, in PWH remain sparse ^{10,11}

99 Studies on the severity of breakthrough COVID-19 illness by HIV status are equivocal, some finding comparable severity,¹²⁻¹⁵ while others have reported a higher risk of developing severe illness and worse 100 outcomes, including death, for PWH compared to PWoH.¹⁶⁻¹⁹ Immune dysfunction is believed to increase 101 severe COVID-19 illness risk in PWH, with lower CD4 counts and detectable HIV viral loads associated with 102 worse outcomes.^{20,21} A higher risk of severe illness in PWH may be confounded by the greater comorbidity 103 104 burden among PWH (compared to similar aged PWoH), including hypertension, diabetes, cardiovascular disease, and smoking.^{22,23} Conversely, PWH have greater immune dysfunction and a lower likelihood of 105 hyperactive cytokine response, which may reduce the risk of severe illness in PWH.²² With global COVID-19 106 vaccination uptake, there is an increasing need to estimate severe COVID-19 breakthrough illness rates and 107 108 risk among PWH and an appropriate control group. However, large cohorts are needed to observe sufficient 109 breakthrough infections that progress to severe illness.

Current US Centers for Disease Control and Prevention (CDC)'s guidelines recommend risk reduction behaviors (i.e. mask wearing), an additional COVID-19 primary series vaccine dose and second booster dose for PWH having "advanced or untreated HIV infection."^{24,25} PWH having partially recovered CD4 counts and moderate immune suppression are not currently recommended for an additional or second booster dose. Our objective was to determine if HIV infection was associated with increased severe COVID-19 outcomes among fully vaccinated adults with a breakthrough SARS-CoV-2 infection, and to determine the risk factors for severe COVID-19 breakthrough illness among PWH.

117

118 METHODS

119 Study population

The Corona-Infectious-Virus Epidemiology Team (CIVET-II) cohort is comprised of four cohorts
 including Kaiser Permanente Mid-Atlantic States (Maryland, District of Columbia, northern Virginia), Kaiser
 Permanente Northern California, University of North Carolina Chapel Hill HIV Clinic (UNC), and the Veterans
 Aging Cohort Study (VACS), a cohort of PWH (and similar PWoH) receiving care within the National US
 Veterans Affairs Healthcare System. This collaboration is an extension of the North American AIDS Cohort
 Collaboration on Research and Design.²⁶ Each local institution and the Johns Hopkins Bloomberg School of
 Public Health institutional review board granted approval.

Adults (≥18 years old), "in-care" (Supplement Table 1), and fully vaccinated against COVID-19
between December 11, 2020 (Emergency Use Authorization of the first COVID-19 vaccine) and June 30,
2021, were eligible. Full vaccination status was defined using CDC criteria: a) 14 days after BNT162 (Pfizer)
or mRNA-1273 (Moderna) mRNA vaccine second dose; or b) 14 days after Janssen Ad26.COV2.S (J&J)
single dose.²⁷ Patients with vaccines not authorized in the US were excluded.

Fully vaccinated PWH were matched to three PWoH on the date fully vaccinated (+/-14 days of the PWH vaccination date), 10-year age group, race/ethnicity, and sex at birth. Race/ethnicity was included given the disproportionate burdens of HIV by race/ethnicity. To maximize the cohort size, PWH could be matched to individuals one age group above or below their category. If three matches were unavailable, PWH were matched to one or two PWoH. The VACS (N=67,627) matches each Veteran with HIV to two Veterans without HIV per their longstanding schema, based on age, race/ethnicity, sex, and clinical site at cohort entry; VACS participants were not matched on date fully vaccinated.²⁸

Participants were eligible for the present study if they had breakthrough COVID-19, defined as the first SARS-CoV-2 infection (detectable SARS-CoV-2 nucleic acid amplification assay [NAAT] or antigen test) or COVID-19 diagnosis (International Classification of Diseases (ICD)-10 codes [**Supplement Table 2**]) after the date fully vaccinated. Additional detectable SARS-CoV-2 laboratory test results and/or diagnoses occurring within +/- 90 days of breakthrough were considered persistent infection.²⁹ If a COVID-19 diagnosis

144 code was also identified within the 90-day window of detectable result, the first laboratory test was the

145 breakthrough diagnosis date.

All variables were abstracted from electronic health records (EHR). Our study follows the

147 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.

148

149 Outcome: Severe COVID-19 breakthrough illness

150 Severe COVID-19 breakthrough illness was defined as: 1) hospitalization within 28 days of

breakthrough; and 2) discharge diagnosis ranked first or second was COVID-19. All discharge diagnoses

were evaluated by two infectious disease physicians to exclude hospitalizations that were unlikely due to

153 COVID-19 (trauma, surgical, non-COVID-19 infections, mental health, or substance use admissions). Only

the first-ranked discharge diagnosis was available for one cohort (contributing 28% of the study population).

155 In this cohort, if COVID-19 was not the first-ranked discharge diagnosis, and there was ≥1 other discharge

diagnosis suggestive of COVID-19 (i.e., pneumonia due to coronavirus disease, other viral pneumonia, acute

157 respiratory failure, or hypoxemia) the patient was classified as the outcome of severe COVID-19

158 breakthrough illness.

159 Mechanical ventilation and extracorporeal membrane oxygenation (ECMO) procedures were

160 extracted from ICD-10 procedure and current procedural terminology (CPT) codes (**Supplement Table 2**)

occurring between the hospital admission and discharge dates. Death occurring during or within 30 days
 following hospitalization or within 30 days following COVID-19 diagnosis among those not hospitalized was

163 extracted from EHR.

164

165 *Exposure: HIV infection*

PWH were identified using HIV registries or HIV ICD diagnosis codes (Supplement Table 1). PWoH
 were classified as such if there was no evidence of HIV infection using these same sources as of December
 11, 2020.

169

170 Covariates

	It is made available under a CC-BY-NC-ND 4.0 International license .
171	Demographic covariates included age, race/ethnicity, and sex at birth. COVID-19 covariates included
172	the primary series vaccine type (Pfizer, Moderna, J&J), additional vaccine dose (receipt ≥28 days after
173	completion of primary series), and SARS-CoV-2 infection prior to date fully vaccinated (history of COVID-19).
174	History of COVID-19 included both infections occurring prior to any vaccination or in the window between the
175	first dose and full vaccination (partial breakthrough).
176	Comorbidity covariates included obesity (body mass index [BMI] ≥30 kg/m ²), type 2 diabetes (DM),
177	hypertension (HTN), end-stage renal disease (ESRD), immune suppressive conditions (organ or tissue
178	transplantation [SOT], rheumatoid arthritis [RA], systemic lupus erythematosus [SLE]), cancer, and
179	pregnancy. Comorbidity diagnoses were identified using ICD-10 codes, measured closest to the date fully
180	vaccinated and after October 1, 2015; or January 1, 2020, for cancer and pregnancy only (see Supplement
181	Table 2 for ICD-10 diagnosis codes).
182	Among PWH, CD4 T-cell count, and HIV-1 plasma RNA viral load suppression were collected closest
183	to the date of full vaccination after January 1, 2020, and at antiretroviral therapy initiation (12 months prior to
184	1 month after). HIV viral suppression was defined as <50 copies/mL. History of AIDS diagnosis (clinical
185	diagnosis ³⁰ or CD4 count <200 cells/mm ³) prior to date fully vaccinated was included.
186	
187	Statistical analysis

Study entry was the date of observed breakthrough COVID-19. Individuals were followed to date of severe breakthrough COVID-19 illness (outcome) or date of death, disenrollment from the health system (applicable to 2 of the health systems), 28 days after breakthrough COVID-19, or December 31, 2021,

191 whichever occurred first.

Severe COVID-19 breakthrough illness monthly incidence rates (IR) per 100 person-years (PY) and 95% confidence intervals ([,]) were calculated by HIV status. Severe COVID-19 breakthrough illness cumulative incidence was estimated from the date of breakthrough COVID-19 through day 28; estimates were stratified by HIV status, and among PWH, CD4 count (<350, 350-499, and \geq 500 cells/mm³) and viral suppression status. Using the same timescale, cumulative incidence was also estimated by HIV status for each vaccine type and for those who received an additional vaccine dose (\geq 28 days after primary series

completion and prior to breakthrough COVID-19). Log-rank tests were calculated to test for differences in
 cumulative incidence and risk differences were estimated (with standard error or Wald 95% confidence
 intervals).

201 A discrete time-to-event analysis using a complimentary log-log model estimated the unadjusted and adjusted hazard ratios (aHR) with 95% confidence intervals for severe COVID-19 breakthrough illness risk by 202 HIV status. Adjustment factors included: sex, race/ethnicity, age, additional vaccine dose following primary 203 series, prior COVID-19, obesity, DM, HTN, ESRD, SOT, RA, SLE, cancer, and cohort. Subgroup analyses 204 205 stratified by HIV status allowed for investigations into risk factors for severe COVID-19 breakthrough illness in both groups. Among PWH, prior AIDS diagnosis, HIV viral suppression and CD4 count were evaluated as 206 207 risk factors for severe COVID-19. Sensitivity analyses excluded participants without first or second diagnosis 208 code rankings.

209

210 **RESULTS**

211 Among 113,994 patients (33,029 PWH and 80,965 PWoH), there were 3,649 breakthrough COVID-212 19 infections (1,241 PWH and 2,408 PWoH). Of those who experienced a COVID-19 breakthrough infection, 60% were \geq 55 years, 89% were male, 47% were non-Hispanic Black, 59% received Pfizer and 31% 213 received Moderna for their primary series, and 15% received an additional COVID-19 vaccine dose ≥28 days 214 215 after primary series completion (20% in PWH and 13% in PWoH). PWH who had CD4 count of <200 cells/mm³ (17%) and 200-349 cells/mm³ (16%) were less likely to receive an additional vaccine dose, 216 compared to PWH with CD4 counts \geq 350 cells/mm³ (20%) (Supplemental Table 3). Among the N=3,649 217 218 patients with breakthrough COVID, the majority (75%) were laboratory confirmed and the remainder were based on clinical diagnosis codes. Forty-nine percent of breakthroughs occurred during the Delta variant 219 220 (B.1.617.2) surge from July-Oct 2021, and 41% occurred from Nov-Dec 2021 (the start of the Omicron variant [B.1.1.529] wave) (Table 1). PWH (compared with PWoH) had a lower proportion with obesity (36% 221 vs. 54%), DM (25% vs. 34%), and HTN (51% vs. 60%) prior to vaccination. The proportion with ESRD, RA, 222 SLE, or having received a SOT or a cancer diagnosis were similar by HIV status. Among PWH, 26% had 223

- history of AIDS prior to vaccination, 91% were virally suppressed and median CD4 count was 620
- (interguartile range [IQR]: 438, 846) cells/mm³ at the time fully vaccinated.
- Among those with breakthrough COVID-19, 249 (7% overall; 79 or 6% of PWH; 170 or 7% PWoH)
- had severe COVID-19 breakthrough illness and were hospitalized (**Table 1** and **Supplement Figure 1**). Most
- (66%) hospitalizations occurred on the same day, and 81% occurred within two days following COVID-19
- diagnosis. The median duration of hospitalization was 5 (IQR: 3, 8) days among PWoH and 4 (IQR: 2, 8)
- 230 days among PWH. Among all hospitalized patients 10% were mechanically ventilated (Table 1). There were
- 33 deaths (1% overall; 12 or 1% in PWH; 21 or 1% in PWoH) that occurred during or within 30 days of
- 232 hospital discharge or COVID-19 diagnosis. Supplement Table 4 describes characteristics stratified by HIV
- status and severe COVID-19 breakthrough illness status.
- 234

235 Incidence Rates (IR) and Cumulative Incidence of Severe COVID-19 Breakthrough Illness

The IR of severe COVID-19 breakthrough illness was higher among PWoH (138 [118, 160] /100 PY)

versus PWH (117 [92, 145] /100 PY) (Figure 1) and relatively stable over time (Figure 1, Supplement Table

5) with slight fluctuations reflecting the bimodal distribution of the Delta and Omicron variant waves

239 (Supplement Figure 2).

240 The 28-day severe COVID-19 breakthrough illness cumulative incidence was similar among PWoH

241 (7.3% [6.3%, 8.4%]) versus PWH (6.7% [5.2% 8.1%], log rank p=0.399, risk difference=-0.67% [-2.58%,

1.23%]) (**Figure 2a**). PWH with lower CD4 counts (<350 cells/mm³) at full vaccination had a higher risk of

severe COVID-19 breakthrough illness compared with both PWoH and PWH with CD4 counts vs. ≥350

cells/mm³ (Figure 2b, Supplement Figure 3). Risk did not differ by HIV viral load (Figure 2c).

245 Severe COVID-19 breakthrough illness risk was highest among patients with J&J for their primary

246 vaccine series (9.3% [6.1, 12.4%]), followed by Pfizer (7.2% [6.1%, 8.3%]) and Moderna (6.2% [4.8%, 7.7%])

247 (Figure 3a), with no statistically significant differences by HIV status within each vaccine group. Regardless

of the primary vaccine series type, having an additional dose reduced the risk of severe COVID-19

breakthrough illness in both PWH and PWoH (log-rank p=0.021, **Figure 3b**)

250

251 Risk factors for Severe COVID-19 Breakthrough Illness, by HIV status

252 There was no difference in severe COVID-19 breakthrough illness risk in PWH vs. PWoH (aHR=1.02 253 [0.76, 1.35]); however, there was a 59% increased risk among PWH having a CD4 count <350 cells/mm³ 254 compared with PWoH (aHR=1.59 [0.99, 2.46], **Table 2**). Stratified by HIV status, PWH and PWoH had an increased risk of severe COVID-19 breakthrough illness with increasing age and decreased risk among 255 256 those with an additional vaccine dose. Among PWH, severe COVID-19 breakthrough illness risk increased with decreasing CD4 count 257 (compared to CD4 ≥500 cells/mm³: 200-349 cells/mm³ aHR=1.65 [0.80, 3.21]: <200 cells/mm³ aHR=2.57 258 [1.15, 5.29]; **Table 2**). Female PWH had a nearly 3-fold increased severe COVID-19 breakthrough risk 259 260 compared to males. Increased risk associated with non-Hispanic Black and Hispanic race/ethnicity and comorbidities ranged from 12% to 54% (p>0.05). Having a cancer diagnosis was associated with nearly 2-261 262 fold increased risk of severe COVID-19 breakthrough illness (aHR=1.97 [1.05, 3.51]). 263 Among PWoH, females had a reduced risk of severe COVID-19 breakthrough illness compared with 264 males (p>0.05, **Table 2**). There was no observed difference in risk by race, obesity, DM, RA, SLE or having a 265 cancer diagnosis; but there was a 4.5-fold (aHR=4.51 [2.35, 9.80]) increased risk with HTN and 2.5-fold increased risk with ESRD (aHR=2.53 [1.33, 4.56]) and SOT (aHR=2.49 [1.20, 4.96]). 266 267 Sensitivity analyses excluding patients without diagnosis code rankings did not gualitatively change 268 findings. 269 270 Mechanical ventilation, and death in severe COVID-19 breakthrough illness Among the 249 hospitalized patients, a greater proportion of patients with CD4 counts <350 271 cells/mm³ required mechanical ventilation or died during hospitalization compared to PWH with higher CD4 272 273 counts and PWoH (Supplement Figure 4). No patients received ECMO. Patients who needed mechanical ventilation (n=24) or died (n=33) were older (\geq 55 years), male, non-274 275 Hispanic Black, had high proportions of comorbidities, and low uptake (10-13%) of additional vaccine doses 276 (Supplemental Table 6). Of those who had a known death during or within 30 days following COVID-19 277 hospitalization (n=33), the majority had comorbidities including obese BMI (68%), HTN (95%), DM (65%),

- ESRD (30%), SOT (20%), RA (10%), or a cancer diagnosis (25%). Among PWH who died during a severe COVID-19 breakthrough illness (n=12), 50% had a prior diagnosis of AIDS and their median CD4 count at fully vaccinated was 352 (IQR 291, 423) cells/mm³.
- 281

282 DISCUSSION

Prior CIVETs collaboration analyses showed a 28% increase in breakthrough COVID-19 among PWH 283 compared with PWoH.⁴ Our present findings show the risk of severe illness (requiring hospitalization) after 284 285 COVID-19 breakthrough was low (7% of 3,649 vaccinated PWH and PWoH) and did not differ by HIV status overall. PWH with lower CD4 counts (<350cells/mm³), however, had a 59% increase in the risk of severe 286 287 COVID-19 breakthrough illness compared to PWoH, suggesting a role of immune dysfunction in the 288 increased risk. The lack of difference in severe COVID-19 breakthrough illness risk between PWoH and 289 PWH with higher CD4 counts may be due to engagement in medical care, different healthcare seeking 290 behaviors and reduced comorbidities among the PWH included compared to PWoH. The increased risk of severe COVID-19 breakthrough illness for PWH with moderate (CD4 200-349 cells/mm³) immune 291 292 suppression suggests they should be included with those who have advanced or untreated HIV in 293 recommendations for additional primary series vaccination doses, second booster doses, and counseled on 294 risk-reduction strategies.

295 Sex, age, comorbidities, and additional vaccine doses impact the risk of severe COVID-19 breakthrough illness.^{10,31-33} Among both PWoH and PWH, increasing age was the most significant risk factor 296 for severe COVID-19 breakthrough illness in our study. Female PWoH had reduced risk, which has been 297 previously documented;³⁴⁻³⁶ however, female PWH had increased severe risk. It is known that males and 298 females have distinct immune system responses with females often demonstrating increased immune 299 300 competence and less inflammatory immune responses, possibly contributing to their reduced risk for severe COVID-19 breakthrough illness; however, immune dysfunction with HIV may alter this effect and requires 301 302 further investigation.^{34,37,38} Despite recommendations for additional COVID-19 vaccine doses being based inpart on CD4 count,²⁵ we identified that the proportion of PWH who received additional doses varied little by 303 304 CD4 count and was likely driven by clinical decision making and patient preference.

305	Among PWoH, several comorbidities have been associated with increased severe COVID-19
306	breakthrough illness risk. ^{32,33,39} Our findings suggest an increased risk with HTN, ESRD, and SOT.
307	Comorbidities were prevalent among those who experienced a severe COVID-19 breakthrough illness with
308	90% having a diagnosis of obesity, DM, HTN or ESRD. A lower proportion of PWH had at least one
309	comorbidity than PWoH (82% vs 94%), yet their severe COVID-19 breakthrough rates remained the same as
310	PWoH. Moderate to severe immune suppression from HIV itself is an important comorbidity that increases
311	severe COVID-19 breakthrough risk; additional comorbidities and a recent cancer diagnosis increased
312	severe COVID-19 breakthrough risk in PWH.

- 313
- 314 Limitations

315 Our findings may not be generalizable to all PWH, as our study population had a greater proportion of 316 males (89%) than found in the US population of PWH, and those with higher barriers to accessing healthcare 317 (who may be at greater risk for COVID-19) were less likely to be included in our study population. Other 318 outcome data, including mechanical ventilation and death (particularly if death occurred out of hospital) may 319 be under-ascertained. The discharge diagnosis ranking was not consistent as one cohort was only able to 320 provide the primary diagnosis with the remainder unranked; however, a sensitivity analyses demonstrated no 321 significant differences in results following exclusion of this cohort. All discharge diagnoses were reviewed by 322 clinicians to increase specificity in our classification of COVID-19 hospitalization, but discharge coding can be influenced by many factors including reimbursement practices. Similarly, our matching schema was not 323 324 consistent, but the distributions of matching factors indicate that our sample of PWH and PWoH were 325 comparable; we included the matching factors in multivariable analyses to address residual confounding.

326

327 Conclusions

It was uncommon for COVID-19 breakthrough illness to progress to severe illness in our population of PWH and PWoH; however, PWH with moderate immune suppression (200-349 cells/mm³) had an increased severe COVID-19 breakthrough illness risk (compared to PWoH) and may benefit from being included in the CDC's recommendation for those with "advanced and untreated HIV" to receive an additional dose in the

332 primary COVID-19 vaccination series and second booster vaccination. Clinicians should continue to promote

risk-reduction measures among PWH. The increased risk of severe COVID-19 breakthrough illness in PWH

- 334 with moderate and severe immune suppression merits ongoing surveillance to inform vaccine
- recommendations as the pandemic persists, immunity to primary vaccine series and booster doses wane,
- and new variants emerge.
- 337

- 339 Funding statement:
- 340 This project was made possible with supplemental funds to the North American AIDS Cohort Collaboration
- on Research and Design (NA-ACCORD, U01AI069918) from the National Institute of Allergy and Infectious
- 342 Diseases (NIAID).
- 343
- The NA-ACCORD is supported by National Institutes of Health grants U01Al069918, F31Al124794,
- 345 F31DA037788, G12MD007583, K01Al093197, K01Al131895, K23EY013707, K24Al065298, K24Al118591,
- 346 K24DA000432, KL2TR000421, N01CP01004, N02CP055504, N02CP91027, P30Al027757, P30Al027763,
- 347 P30Al027767, P30Al036219, P30Al050409, P30Al050410, P30Al094189, P30Al110527, P30MH62246,
- 348 R01AA016893, R01DA011602, R01DA012568, R01AG053100, R24Al067039, R34DA045592,
- 349 U01AA013566, U01AA020790, U01AI038855, U01AI038858, U01AI068634, U01AI068636, U01AI069432,
- 350 U01Al069434, U01DA036297, U01DA036935, U10EY008057, U10EY008052, U10EY008067,
- 351 U01HL146192, U01HL146193, U01HL146194, U01HL146201, U01HL146202, U01HL146203,
- 352 U01HL146204, U01HL146205, U01HL146208, U01HL146240, U01HL146241, U01HL146242,
- 353 U01HL146245, U01HL146333, U24AA020794, U54GM133807, UL1RR024131, UL1TR000004,
- 354 UL1TR000083, UL1TR002378, UL1TR002489, Z01CP010214 and Z01CP010176; contracts CDC-200-2006-
- 18797 and CDC-200-2015-63931 from the Centers for Disease Control and Prevention, USA; contract
- 356 90047713 from the Agency for Healthcare Research and Quality, USA; contract 90051652 from the Health
- 357 Resources and Services Administration, USA; the Grady Health System; grants CBR-86906, CBR-94036,
- 358 HCP-97105 and TGF-96118 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of

359	Health and Long Term Care, and the Government of Alberta, Canada. Additional support was provided by
360	the National Institute Of Allergy And Infectious Diseases (NIAID), National Cancer Institute (NCI), National
361	Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute Of Child Health &
362	Human Development, National Human Genome Research Institute (NHGRI), National Institute for Mental
363	Health (NIMH) and National Institute on Drug Abuse (NIDA), National Institute On Aging (NIA), National
364	Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Neurological Disorders And
365	Stroke, National Institute Of Nursing Research (NINR), National Institute on Alcohol Abuse and Alcoholism
366	(NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), and National Institute
367	of Diabetes and Digestive and Kidney Diseases (NIDDK).
368	

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the US Centers for Disease Control and Prevention or the US Government

371 of Department of Veterans Affairs.

372

373 **Competing interests:**

KN Althoff reports grants from the National Institutes of Health (NIH, paid to institution) and consultancy to
 the All of Us Research Program (NIH), TrioHealth, Kennedy Dundas, and MedIQ (paid to her).

376

S Napravnik, LE Browne, JK Edwards, LS Park, MA Horberg, CR Jefferson, JM Certa, J Skarbinski report grants from the NIH (paid to institution). KA Gebo reports grants from the NIH and Department of Defense (paid to the institution). R Lang reports grants from CIHR, Alberta Innovates, and the University of Calgary (paid to institution). VC Marconi has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV.

382

BC Hogan, SB Coburn, E Humes, W Leyden, C Stewart, E Watson, KS Gordon, AC Justice, MJ Silverberg,
DM Agil, KM Akgün, CF Williams report no conflicts of interest.

385

386 REFERENCES

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 387 1. Vaccine. N Engl J Med. Dec 31 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 388 Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 389 2. Vaccine. N Engl J Med. Feb 4 2021;384(5):403-416. doi:10.1056/NEJMoa2035389 390 Sadoff J. Grav G. Vandebosch A. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine 391 3. 392 against Covid-19. N Engl J Med. Jun 10 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544 393 4. Coburn SB, Humes E, Lang R, et al. COVID-19 infections post-vaccination by HIV status in the 394 United States. medRxiv. Dec 5 2021;doi:10.1101/2021.12.02.21267182 Sun J, Zheng Q, Madhira V, et al. Association Between Immune Dysfunction and COVID-19 395 5. Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA Intern Med. Dec 28 396 397 2021:doi:10.1001/iamainternmed.2021.7024 Kim AHJ, Nakamura MC. COVID-19 Breakthrough Infection Among Immunocompromised Persons. 398 6. 399 JAMA Intern Med. Dec 28 2021;doi:10.1001/jamainternmed.2021.7033 400 7. Yamamoto S, Maeda K, Matsuda K, et al. COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching 401 402 study. Clin Infect Dis. Dec 24 2021;doi:10.1093/cid/ciab1048 403 Team CC-VBCI. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, 8. 404 January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. May 28 2021;70(21):792-793. 405 doi:10.15585/mmwr.mm7021e3 Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of COVID-19 vaccine responses 406 9. 407 across a broad spectrum of immunocompromising conditions: the COVICS study. Clin Infect Dis. Feb 18 408 2022;doi:10.1093/cid/ciac103 Butt AA, Yan P, Shaikh OS, Mayr FB. Outcomes among patients with breakthrough SARS-CoV-2 409 10. 410 infection after vaccination in a high-risk national population. EClinicalMedicine. Oct 2021;40:101117. 411 doi:10.1016/i.eclinm.2021.101117 412 11. Lin DY, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. Mar 10 2022;386(10):933-941. doi:10.1056/NEJMoa2117128 413 414 Collins LF, Moran CA, Oliver NT, et al. Clinical characteristics, comorbidities and outcomes among 12. 415 persons with HIV hospitalized with coronavirus disease 2019 in Atlanta, Georgia. AIDS. Oct 1 416 2020;34(12):1789-1794. doi:10.1097/QAD.000000000002632 417 Shalev N, Scherer M, LaSota ED, et al. Clinical Characteristics and Outcomes in People Living With 13. Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019. Clin Infect Dis. Nov 19 418 419 2020;71(16):2294-2297. doi:10.1093/cid/ciaa635 Ceballos ME, Ross P, Lasso M, et al. Clinical characteristics and outcomes of people living with HIV 420 14. hospitalized with COVID-19: a nationwide experience. Int J STD AIDS. Apr 2021;32(5):435-443. 421 422 doi:10.1177/0956462420973106 Durstenfeld MS, Sun K, Ma Y, et al. Association of HIV infection with outcomes among adults 423 15. 424 hospitalized with COVID-19. AIDS. Mar 1 2022;36(3):391-398. doi:10.1097/QAD.000000000003129 Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-425 16. based cohort analysis of UK primary care data and linked national death registrations within the 426 427 OpenSAFELY platform. Lancet HIV. Jan 2021;8(1):e24-e32. doi:10.1016/S2352-3018(20)30305-2 Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 Outcomes Among Persons Living With or 428 17. Without Diagnosed HIV Infection in New York State. JAMA Netw Open. Feb 1 2021;4(2):e2037069. 429 430 doi:10.1001/jamanetworkopen.2020.37069 Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-431 18. 432 19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 433 Nov 2021;8(11):e690-e700. doi:10.1016/S2352-3018(21)00239-3 434 Dong Y, Li Z, Ding S, et al. HIV infection and risk of COVID-19 mortality: A meta-analysis. Medicine 19. 435 (Baltimore). Jul 2 2021;100(26):e26573. doi:10.1097/MD.000000000026573 Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in 436 20. HIV/AIDS patients: a systematic review. HIV Med. Oct 2020;21(9):567-577. doi:10.1111/hiv.12911 437 16

438 21. Hoffmann C, Casado JL, Harter G, et al. Immune deficiency is a risk factor for severe COVID-19 in 439 people living with HIV. HIV Med. May 2021;22(5):372-378. doi:10.1111/hiv.13037 22. Lesko CR, Bengtson AM. HIV and COVID-19: Intersecting Epidemics With Many Unknowns. Am J 440 441 Epidemiol. Jan 4 2021;190(1):10-16. doi:10.1093/aje/kwaa158 Hadi YB, Nagvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients 442 23. 443 with HIV: a multicentre research network study. AIDS. Nov 1 2020:34(13):F3-F8. 444 doi:10.1097/QAD.000000000002666 445 24. Centers for Disease Control and Prevention. COVID-19 Vaccines for Moderately to Severely 446 Immunocompromised People Updated Feb 17, 2022. Accessed March 14, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html 447 25. 448 Centers for Disease Control and Prevention (CDC). COVID-19 and HIV. Accessed March 31, 2022. 449 https://www.cdc.gov/hiv/covid-19/index.html 450 Gange SJ, Kitahata MM, Saag MS, et al. Cohort profile: the North American AIDS Cohort 26. 451 Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol. Apr 2007;36(2):294-301. 452 doi:10.1093/ije/dyl286 453 27. When You've Been Fully Vaccinated | CDC. https://www.cdc.gov/coronavirus/2019ncov/vaccines/fully-vaccinated.html. Accessed January 4, 2022. 454 455 28. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the 456 National VA Health Information System. Med Care. Aug 2006;44(8 Suppl 2):S25-30. 457 doi:10.1097/01.mlr.0000223670.00890.74 458 29. Investigative Criteria for Suspected Cases of SARS-CoV-2 Reinfection (ICR) | CDC. 459 https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html. Accessed January 4, 2022. 460 Centers for Disease Control and Prevention. AIDS-Defining Conditions. MMWR Recommendations 30. 461 and Reports. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm Published December 5, 2008. 462 Accessed January 4, 2021. Botton J, Semenzato L, Jabagi MJ, et al. Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 463 31. 464 Vaccine for COVID-19 Hospitalizations. JAMA Netw Open. Mar 1 2022;5(3):e220868. 465 doi:10.1001/jamanetworkopen.2022.0868 Wright BJ, Tideman S, Diaz GA, French T, Parsons GT, Robicsek A. Comparative vaccine 466 32. 467 effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. 468 Lancet Respir Med. Feb 25 2022;doi:10.1016/S2213-2600(22)00042-X 469 33. Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection 470 against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in 471 Italy: retrospective cohort study. BMJ. Feb 10 2022;376:e069052. doi:10.1136/bmj-2021-069052 472 34. Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more 473 vulnerable? Biol Sex Differ. Sep 18 2020:11(1):53. doi:10.1186/s13293-020-00330-7 474 35. Vahidy FS, Pan AP, Ahnstedt H, et al. Sex differences in susceptibility, severity, and outcomes of 475 coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS One. 476 2021;16(1):e0245556. doi:10.1371/journal.pone.0245556 477 36. Liu C, Lee J, Ta C, et al. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough 478 Infections - Risk Factors and Vaccine Effectiveness. medRxiv. Oct 7 2021;doi:10.1101/2021.10.05.21264583 479 Strandberg TE, Pentti J, Kivimaki M. Sex Difference in Serious Infections: Not Only COVID-19. 37. 480 Epidemiology. Nov 1 2021;32(6):e26-e27. doi:10.1097/EDE.00000000001408 38. Qi S, Ngwa C, Morales Scheihing DA, et al. Sex differences in the immune response to acute COVID-481 19 respiratory tract infection. Biol Sex Differ. Dec 20 2021;12(1):66. doi:10.1186/s13293-021-00410-2 482 483 Butt AA, Yan P, Shaikh OS, Mayr FB, Omer SB. Rate and Risk Factors for Severe/Critical Disease 39. Among Fully Vaccinated Persons with Breakthrough SARS-CoV-2 Infection in a High-risk National 484 485 Population. Clin Infect Dis. Dec 10 2021;doi:10.1093/cid/ciab1023 486

Table 1: Characteristics at date of SARS-CoV-2 breakthrough infection, N=3,649

Characteristic	PWoH, N = 2,408 ¹	PWH, N = 1,241 ¹
Hospitalization	170 (7%)	79 (6%)
Mechanical Ventilation among those hospitalized	16 (9%)	8 (10%)
Death among breakthrough infections	21 (1%)	12 (1%)
Age		
18-24	9 (0%)	9 (1%)
25-34	137 (6%)	112 (9%)
35-44	279 (12%)	184 (15%)
45-54	492 (20%)	245 (20%)
55-64	797 (33%)	359 (29%)
65-74	539 (22%)	264 (21%)
75+	155 (6%)	68 (6%)
Sex		
Male	2,108 (88%)	1,136 (92%)
Female	300 (13%)	105 (9%)
Ethnicity and Race		
Non-Hispanic white	744 (31%)	421 (34%)
Non-Hispanic Black/African American	1,151 (48%)	555 (45%)
Hispanic	366 (15%)	183 (15%)
Other	131 (5%)	71 (6%)
Unknown	16 (1%)	11 (1%)
Month of breakthrough		
Jan-June	247 (10%)	134 (11%)
July-Oct	1,132 (47%)	639 (51%)
Nov-Dec	1,029 (43%)	468 (38%)
Primary vaccination series type		
Pfizer	1,194 (50%)	605 (49%)
Pfizer + 3rd dose	194 (8%)	165 (13%)
Moderna	676 (28%)	301 (24%)
Moderna + 3rd dose	95 (4%)	68 (6%)
1&1	234 (10%)	93 (7%)
J&J + 2nd dose	15 (1%)	9 (1%)
COVID prior to fully vaccinated	292 (12%)	176 (14%)
Comorbidities at fully vaccinated		
Obese BMI (≥30 kg/m²)	1,218 (54%)	434 (36%)

Characteristic	PWoH, $N = 2,408^{1}$	PWH, $N = 1,241^{1}$
Diabetes	817 (34%)	308 (25%)
Hypertension	1,443 (60%)	633 (51%)
End-stage renal disease	63 (3%)	38 (3%)
Immune suppressive conditions at fully vaccinated		
Organ or tissue transplantation	43 (2%)	18 (2%)
Rheumatoid arthritis	44 (2%)	14 (1%)
Lupus	10 (0%)	3 (0%)
Cancer diagnosis	187 (8%)	129 (10%)
Pregnancy	4 (0%)	3 (0%)
CD4 at ART initiation (cells/mm ³)		393(234, 613)
unknown		536 (43%)
AIDS before fully vaccinated		325 (26%)
CD4 at fully vaccinated (cells/mm ³)		620 (438, 846)
<200		54 (4%)
200-349		109 (9%)
350-499		182 (15%)
≥500		707 (57%)
unknown		189 (15%)
Suppressed HIV RNA at fully vaccinated (<50 copies/mL)		1,016 (91%)
unknown		120 (10%)

¹n (%) except for CD4 counts where the medians (interquartile ranges) are reported Definitions:

- Death defined as died while hospitalized for COVID-19 or within 30 days following discharge or within 30 days of COVID-19 diagnosis among those not hospitalized.

- Mechanical Ventilation: Measured during the dates of hospital admission and discharge.

- Age was categorized in 5-year increments for descriptive purposes


- BMI, Diabetes, Hypertension, ESRD, Organ or tissue transplantation, RA, Lupus: Measured as close to the date fully vaccinated as possible within the window of 10/1/2015 – date fully vaccinated.

- Cancer, Pregnancy: Measured as close to the date fully vaccinated as possible within the window of 1/1/2020 – date fully vaccinated

- AIDS was defined using clinical diagnosis codes of AIDS-defining conditions.

Abbreviations: AIDS, acquired immunodeficiency syndrome ART, antiretroviral Therapy BMI, body mass index COVID-19, Coronavirus Disease 2019 ESRD, end-stage renal disease HIV, human immunodeficiency virus PWH, people with HIV PWoH, people without HIV RA, rheumatoid arthritis


Figure 1: Incidence Rates of Severe COVID-19 breakthrough per 100 patient-years (PY) in people with and without HIV by month (along with 95% CI) (N=3,649)



Footnote:

The incidence rate estimates for January 2021 were not estimated as there were 0 and 0.02 person-years of observation after COVID-19 breakthrough infection in PWH and PWoH, respectively. Similarly, the person years in February 2021 were 0.14 and 0.21 in PWH and PWoH (respectively) and there were no severe COVID-19 breakthrough illness events; incidence rates were not estimated.


Figure 2: Cumulative incidence of severe COVID-19 breakthrough illness (and 95% confidence intervals represented by the shading), stratified by a) HIV status, b) CD4 count and HIV status, and c) HIV viral suppression and HIV status



a) severe COVID-19 breakthrough illness, by HIV status


Footnotes: Log-rank test p=0.399.


b) severe COVID-19 breakthrough illness, by CD4 count and HIV status



Footnotes: Log-rank test including PWoH: p=<0.001.

Log-rank test after excluding PWoH: p=<0.001.






Footnotes:

Log-rank test including PWoH: p=0.309.

Log-rank test after excluding PWoH: p=0.284.


Virally suppressed defined by HIV-1 RNA viral load <50 copies/mL.

Figure 3: Cumulative incidence of severe COVID-19 breakthrough illness (and 95% confidence intervals represented by the shading), stratified by HIV status and primary vaccination series type



Footnotes:

Log rank test for J&J: p=0.404 Log rank test for Pfizer: p=0.665 Log rank test for Moderna: p=0.15



Cumulative incidence of hospitalization

Log rank test: p=0.021

 Table 2: Crude (HR) and adjusted hazard ratios (aHR) and 95% confidence intervals (CI) of severe SARS-CoV-2 breakthrough illness

Cov-2 breakthrough liness	Total Population (N=3,385)				
HIV status	HR (95% CI) 1.00 2.00 (1.26, 3.02) 0.70 (0.50, 0.97)		^a aHR (95% CI) 1.00 1.59 (0.99, 2.46) 0.95 (0.67, 1.32)		
PWoH PWH, CD4 count <350cells/mm ³ PWH, CD4 count ≥350cells/mm ³					
Characteristics	^a PWoH (N=2,		^b PWH (N=	1,035 n=68)	
	HR (95% CI)	aHR (95% CI)	HR (95% CI)	aHR (95% CI)	
Sex	4.00	4.00	4.00	4.00	
Male	1.00	1.00	1.00	1.00	
Female	0.25 (0.10, 0.52)	0.48 (0.16, 1.12)	1.50 (0.66, 2.95)	2.88 (1.03, 7.11)	
Ethnicity and Race		4.00	4.00	4.00	
Non-Hispanic white		1.00	1.00	1.00	
Non-Hispanic Black/African American	1.24 (0.88, 1.77)	1.26 (0.86, 1.85)	1.26 (0.73, 2.22)	1.26 (0.70, 2.32)	
Hispanic	1.01 (0.61, 1.62)	1.21 (0.72, 1.98)	0.98 (0.43, 2.10)	1.54 (0.65, 3.38)	
Other/Unknown	0.52 (0.18, 1.19)	1.24 (0.43, 2.86)	1.30 (0.43, 3.21)	2.71 (0.87, 7.12)	
Age	1.00	4.00	1.00	4.00	
<55	1.00	1.00	1.00	1.00	
55-64	6.63 (3.54, 13.80)	3.49 (1.74, 7.86)	3.02 (1.52, 6.33)	2.11 (0.98, 4.80)	
65-74	12.60 (6.82, 26.00)	5.37 (2.64, 12.20)	4.41 (2.25, 9.13)	3.01 (1.37, 6.98)	
75+ Primary vaccination parios type	21.00 (10.70, 45.00)	8.44 (3.90, 20.00)	7.71 (3.25, 17.9)	5.21 (1.88, 14.40)	
Primary vaccination series type	1.00	1 00	1.00	1.00	
Primary Series only	1.00	1.00	1.00 0.43 (0.17, 0.91)	1.00	
Primary Series + additional dose	0.63 (0.34, 1.07)	0.56 (0.29, 0.98)	0.43 (0.17, 0.91)	0.47 (0.18, 1.04)	
COVID-19 prior to fully vaccinated Calendar period of breakthrough	0.39 (0.18, 0.71)	0.21 (0.09, 0.40)	0.43(0.15, 0.97)	0.22 (0.07, 0.52)	
Jan – June	1.00		1.00		
July – Oct	1.49 (0.91, 2.62)		2.53 (1.03, 8.40)		
Nov – Dec	0.77 (0.45, 1.40)		1.41 (0.53, 4.89)		
Comorbidities before fully vaccinated	0.77(0.43, 1.40)		1.41 (0.55, 4.89)		
Obese BMI (≥30 kg/m ² vs. <30)	0.98 (0.72, 1.34)	1.01 (0.73, 1.40)	1.38 (0.85, 2.23)	1.46 (0.85, 2.49)	
Diabetes (vs. no)	2.80 (2.07, 3.81)	1.11 (0.79, 1.56)	2.26 (1.39, 3.64)	1.47 (0.85, 2.50)	
Hypertension (vs. no)	7.73 (4.65, 14.00)	4.51 (2.35, 9.80)	3.02 (1.78, 5.39)	1.27 (0.67, 2.50)	
End-stage renal disease (vs. no)	6.25 (3.88, 9.58)	2.53 (1.33, 4.56)	1.82 (0.55, 4.41)	1.12 (0.31, 3.09)	
Immune suppressive conditions at fully	0120 (0.00, 0.00)	2.00 (1.00, 4.00)	1.02 (0.00, 4.41)	1.12 (0.01, 0.00)	
vaccinated (vs. no)					
Organ or tissue transplantation	6.79 (3.89, 11.0)	2.49 (1.20, 4.96)	0.95 (0.05, 4.27)	0.55 (0.03, 3.39)	
Rheumatoid arthritis	2.03 (0.80, 4.19)	1.33 (0.50, 2.87)	1.28 (0.07, 5.78)	1.09 (0.06, 5.45)	
Cancer diagnosis	2.64 (1.75, 3.86)	1.47 (0.95, 2.19)	2.92 (1.64, 4.95)	1.97 (1.05, 3.51)	
Lupus ^c	2.86 (0.47, 8.95)		(,,	(,	
AIDS diagnosis before fully vaccinated HIV RNA at fully vaccinated	(,		1.83 (1.11, 2.96)	1.22 (0.70, 2.10)	
Suppressed (<50 copies/mL)			1.00		
Unsuppressed (≥50 copies/mL)			1.43 (0.66, 2.74)		
CD4 count at fully vaccinated			- (
(cells/mm ³)					
≥500			1.00	1.00	
350-499			1.28 (0.62, 2.44)	1.19 (0.56, 2.35)	
200-349			2.52 (1.28, 4.66)	1.65 (0.80, 3.21)	
<200			3.98 (1.86, 7.76)	2.57 (1.15, 5.29)	

Footnotes:

Total number of severe COVID-19 illness events=238.

Abbreviations: HR=crude hazard ratio. aHR=adjusted hazard ratio. 95% CI=95% confidence interval.

^aAdjusted for age (categorized into a 4-level group to assess a dose response relationship among older people (i.e., 55+) that are known to be at greater risk), sex, race and ethnicity, primary vaccination series type, COVID-19 prior to fully vaccinated, Comorbidities before fully vaccinated, immune suppressive conditions at fully vaccinated, and cohort. ^b Adjusted for the covariates in the table and cohort.184(15.1% of all PWH) were excluded due to missing CD4 or HIV RNA measurements.

^c There were no severe COVID-19 breakthrough illnesses among PWH with lupus, and it was therefore excluded from the multivariable model.

Values with P<0.05 are bolded.

SUPPLEMENT

Supplement Table 1: Definitions of in care and criteria used to identify people with (PWH) and without HIV	
(PWoH)	

Cohort	Description	"In care" or "in cohort"	РШН
Kaiser Permanente Mid- Atlantic States (KPMAS)	Integrated Health system	In Care – KPMAS membership for ≥1 month in 2020	HIV registry*
Kaiser Permanente Northern California (KPNC)	Integrated Health system	In Care – KPNC membership for ≥1 month between 3/1/20 and 12/31/20	HIV registry*
University of North Carolina Chapel Hill (UNC)	Medical center cohort	≥1 encounter with UNC Health in 2019 and alive as of 03/01/2020	HIV diagnosis (by ICD diagnosis code)
Veterans Aging Cohort Study (VACS)	National cohort of all PWH and 1:2 demographically-matched PWoH in care in the Veterans Health Administration (VA) system	Enrolled in VACS from 1996-2017 and alive in 2020	HIV diagnosis (presence of 1 inpatient or 2 outpatient ICD codes for HIV)

The Kaiser Permanente Mid-Atlantic States and Northern California HIV Registries are databases of members diagnosed with HIV since 1998 and 1980, respectively. Primary sources used to identify HIV patients are HIV-specific laboratory tests, antiretroviral therapy, hospital-based HIV diagnosis, and diagnosis.

Supplement Table 2: Diagnosis and Procedure codes used to ascertain comorbidities and outcomes

Condition	ICD-10 Diagnosis Codes
COVID-19	U07.1 (specific to COVID), B34.2 (Coronavirus infection, unspecified), B97.21
breakthrough	(SARS-associated coronavirus causing disease classified elsewhere), B97.29 (other
infection	coronavirus as the cause of diseases classified elsewhere, J12.81 (pneumonia due
Between Jan 1, 2020	to SARS-associated coronavirus, or O98.5 COVID in pregnancy, child-birth or
-Dec 31, 2021	postpartum
Immune suppressive	Conditions
Organ or tissue	Z94.x
transplantation	
Rheumatoid Arthritis	M05, M06
Lupus	M32
Cancer	C00-C14, C15-C26, C30-C39, C40-C41, C43-C44, C45-C49, C50, C51-C58, C60-
	C63, C64-C68, C69-C72, C73-C75, C76-C80, C81-C96, C7A, C7B, D45
Pregnancy	Z3A, O00-O16, O20-O48, O60-O77, O80-O82, O94-O9A
Comorbidities	
Diabetes	E11.x
End stage renal	N18.5 CKD stage 5, N18.6 ESRD
disease	
Hypertension	110-115.9, 167.4)
Obesity	E66.x, O99.21x
Outcomes of COVID-1	
Mechanical	ICD-10 procedure codes:
Ventilation	0BH17EZ: Intubation
	5A1945Z: Respiratory Ventilation, 24-96 Consecutive Hours
	5A1955Z: Respiratory Ventilation, Greater than 96 Consecutive Hours
	5A1935Z: Respiratory Ventilation, Less than 24 Consecutive Hours
	5A1522G: Extracorporeal Oxygenation, Perph VA ECMO
	5A15A2G: Extracorporeal Oxygenation, Perph VA ECMO, Intraop
	5A15A2H: Extracorporeal Oxygenation, Perph VV ECMO, Intraop
	CPT codes:
	94002: HC Ventilation Assist & Mgmt Inpatient 1st day
	94003: HC Ventilation Assist & Mgmt Inpatient subsequent days

Supplement Table 3: Proportion of PWH who received additional vaccine doses by CD4 count at fully vaccinated (N=1,241).

CD4 at fully vaccinated (cells/mm ³)	# of COVID-19 breakthroughs in PWH	# who received an additional COVID-19 vaccine
<200	54	9 (17%)
200-349	109	17 (16%)
350-499	182	41 (23%)
≥500	707	141 (20%)
Unknown	189	34 (18%)


Supplement Table 4: Characteristics of SARS-CoV-2 breakthrough infection, both severe and non-severe by HIV status N=3,649

	PWoH N=2,408		PWH N=1,241	
Characteristic	No Severe Breakthrough N = 2,238	Severe Breakthrough N = 170	No Severe Breakthrough N = 1,162	Severe Breakthrough N = 79
Age (years)				
<55	907 (41%)	10 (6%)	534 (46%)	16 (20%)
55-64	741 (33%)	56 (33%)	333 (28%)	26 (33%)
65-74	486 (21%)	71 (42%)	240 (21%)	24 (30%)
75+	122 (5%)	33 (19%)	55 (5%)	13 (16%)
Sex				
Male	1944 (87%)	164 (97%)	1,065 (91%)	71 (90%)
Female	294 (13%)	6 (4%)	97 (8%)	8 (10%)
Ethnicity and Race				
Non-Hispanic White	694 (31%)	50 (29%)	397 (34%)	24 (30%)
Non-Hispanic Black/ African American	1,060 (47%)	91 (54%)	515 (44%)	40 (51%)
Hispanic	342 (15%)	24 (14%)	173 (15%)	10 (13%)
Other	127 (6%)	4 (3%)	66 (6%)	5 (6%)
Unknown	15 (1%)	1 (1%)	11 (1%)	0 (0.0%)
Month of breakthrough				
Jan-June	231 (10%)	16 (9%)	129 (11%)	5 (6%)
July-Oct	1.024 (46%)	108 (64%)	585 (50%)	54 (68%)
Nov-Dec	983 (44%)	46 (27%)	448 (39%)	20 (25%)
Vaccine series				
Pfizer	1,103 (49%)	91 (54%)	559 (48%)	46 (58%)
Pfizer + 3rd dose	187 (8%)	7 (4%)	160 (14%)	5 (6%)
Moderna	629 (28%)	47 (28%)	285 (25%)	16 (20%)
Moderna + 3rd dose	90 (4%)	5 (3%)	67 (6%)	1 (1%)
J&J	215 (10%)	19 (11%)	82 (7%)	11 (14%)
J&J + 2 nd dose	14 (1%)	1 (1%)	9 (1%)	0 (0%)
COVID prior to full vaccination date	283 (13%)	9 (5%)	170 (15%)	6 (8%)
Comorbidities before fully vaccinated				
Obese BMI (>=30 kg/m2)	1,132 (54%)	86 (53%)	402 (36%)	32 (43%)
Diabetes	718 (32%)	99 (58%)	276 (24%)	32 (41%)
Hypertension	1,287 (58%)	156 (92%)	577 (50%)	56 (71%)
End-stage renal disease	41 (2%)	22 (13%)	34 (3%)	4 (5%)
Organ or tissue transplantation	27 (1%)	16 (9%)	17 (1%)	1 (1%)
Rheumatoid arthritis	38 (2%)	6 (4%)	13 (1%)	1 (1%)
Lupus	8 (0%)	2 (1%)	3 (0%)	0 (0%)

	PWoH N=2,408		PWH N=1,241	
Characteristic	No Severe Breakthrough N = 2,238	Severe Breakthrough N = 170	No Severe Breakthrough N = 1,162	Severe Breakthrough N = 79
Cancer diagnosis	157 (7%)	30 (18%)	111 (10%)	18 (23%)
Pregnancy	4 (0%)	0 (0%)	3 (0%)	0 (0%)

Age was categorized into a 4-level group to assess a dose response relationship among older people (i.e., 55+) that are known to be at greater risk.

Supplement Figure 1: Identification of severe COVID-19 breakthrough infections



Supplement Table 5: Severe COVID-19 breakthrough illness Incidence rates and 95% confidence intervals, by month and HIV status


	# of severe COVID-19	# of porcon vooro	IR (95% CI) per 100 person
Tetal	breakthroughs	# of person-years	years
Total	1		-
Overall	249	191.3	137.5 (117.6, 159.8)
PWH	79	67.7	116.7 (92.4, 145.4)
PWoH	170	123.6	130.2 (114.5, 147.4)
Moderna			
Overall	69	61.9	111.5 (86.8, 141.2)
PWH	17	21.0	81.1 (47.3, 129.9)
PWoH	52	40.9	127.1 (94.9, 166.7)
Pfizer			
Overall	149	110.3	135.1 (114.3, 158.7)
PWH	51	41.1	124.1 (92.4, 163.2)
PWoH	98	69.2	141.7 (115.0, 172.7)
J&J			
Overall	31	19.2	161.5 (109.7, 229.2)
PWH	11	5.7	194.4 (97.0, 347.8)
PWoH	20	13.5	147.8 (90.2, 228.2)
	· ·		
By calendar mor	nth		

By ca	llendar mon	ith		
Jan	Overall	0	0.02	0.0 (0.0, 19248.5)
	PWH	0	0	n/a
	PWoH	0	0.02	0.0 (0.0, 19248.1)
	Overall	0	0.35	0.00 (0.00, 1052.6)
Feb	PWH	0	0.14	0.0 (0.0, 2641.9)
	PWoH	0	0.21	0.0 (0.0, 1749.8)
	Overall	2	2.56	78.2 (9.5, 282.5)
Mar	PWH	0	0.90	0.0 (0.0, 409.5)
	PWoH	2	1.66	120.7 (14.6, 436.2)
	Overall	6	6.06	99.0 (36.3, 215.5)
Apr	PWH	1	2.13	47.0 (1.2, 261.6)
	PWoH	5	3.93	127.2 (41.3, 296.8)
	Overall	8	9.07	88.2 (38.1, 173.8)
May	PWH	3	3.13	95.8 (19.8, 272.9)
	PWoH	5	5.94	84.2 (27.3, 196.5)
	Overall	3	7.33	41.0 (8.4, 119.7)
June	PWH	1	2.52	39.7 (1.0, 221.2)
	PWoH	2	4.81	41.6 (5.0, 150.3)
	Overall	16	13.25	120.7 (69.0, 196.1)
Jul	PWH	4	5.60	71.4 (19.5, 182.7)
	PWoH	12	7.65	156.9 (81.1, 274.1)
	Overall	69	44.68	154.4 (120.2, 195.4)
Aug	PWH	25	19.2	130.2 (84.3, 192.2)
	PWoH	44	25.5	172.7 (125.5, 231.8)
	Overall	57	42.40	134.5 (101.8, 174.2)
Sept	PWH	18	13.9	129.9 (77.0, 205.3)
	PWoH	39	28.5	136.7 (97.2, 186.8)
	Overall	20	29.25	68.4 (41.8, 105.6)


Oct	PWH	7	9.5	74.1 (29.8, 152.7)
	PWoH	13	19.8	65.7 (35.0, 112.3)
	Overall	24	19.15	125.3 (80.3, 186.5)
Nov	PWH	7	6.0	117.3 (47.2, 241.8)
	PWoH	17	13.2	128.9 (75.1, 206.4)
	Overall	44	36.67	120.0 (87.2, 161.1)
Dec	PWH	13	11.4	114.4 (60.9, 195.7)
	PWoH	31	25.3	122.5 (83.2, 173.8)


Supplement Figure 2: Histograms of the date of severe SARS-CoV-2 breakthrough infection, by HIV status

a) Calendar time



b) Time from date fully vaccinated to breakthrough





Supplemental Figure 3: Cumulative incidence of severe COVID-19 breakthrough illness (and 95% confidence intervals represented by the shading) stratified by CD4 count and HIV status

Log-rank test: p=<0.001

Supplement Table 6: Characteristics of participants with breakthrough COVID-19 illness requiring hospitalization, mechanical ventilation or in those who died

	Hospitalized (Severe COVID-19)	Mechanical ventilation	Death
Characteristic	N = 249	N = 24	N = 20
HIV Status			
PWoH	170 (68%)	16 (67%)	14 (70%)
PWH	79 (32%)	8 (33%)	6 (30%)
Age (years)			
<55	19 (8%)	3 (13%)	2 (10%)
55-64	82 (33%)	9 (38%)	4 (20%)
65-74	95 (38%)	6 (25%)	5 (25%)
75+	46 (19%)	6 (25%)	9 (45%)
Sex			
Male	235 (94%)	20 (83%)	18 (90%)
Female	14 (6%)	4 (17%)	2 (10%)
Ethnicity and Race			
Non-Hispanic White	74 (30%)	2 (8%)	5 (25%)
Non-Hispanic Black/African American	131 (53%)	18 (75%)	11 (55%)
Hispanic	34 (14%)	4 (17%)	4 (20%)
Other	9 (4%)	0 (0%)	0 (0%)
Unknown	1 (0%)	0 (0%)	0 (0%)
Month of breakthrough			
Jan-June	21 (8%)	3 (13%)	3 (15%)
July-Oct	162 (65%)	16 (67%)	13 (65%)
Nov-Dec	66 (27%)	5 (21%)	4 (20%)
COVID prior to vaccination	15 (6%)	0 (0%)	0 (0%)
Vaccine Series			
Primary Series Only	230 (92%)	21 (88%)	18 (90%)

	Hospitalized	Mechanical	Death
	(Severe COVID-19)	ventilation	Death
Characteristic	N = 249	N = 24	N = 20
Primary Series + additional dose	19 (8%)	3 (13%)	2 (10%)
Obese BMI (>=30 kg/m²)	118 (50%)	20 (87%)	13 (68%)
Unknown	13	1	1
Diabetes	131 (53%)	15 (63%)	13 (65%)
Hypertension	212 (85%)	23 (96%)	19 (95%)
End-stage renal disease	26 (10%)	5 (21%)	6 (30%)
Organ or tissue transplantation	17 (7%)	5 (21%)	4 (20%)
Rheumatoid arthritis	7 (3%)	3 (13%)	2 (10%)
Lupus	2 (1%)	0 (0%)	0 (0%)
Cancer diagnosis	48 (19%)	5 (21%)	5 (25%)
CD4 at ART initiation	399 (212,546)	376 (324,417)	398 (354,855)
Unknown	210	20	15
AIDS before fully vaccinated	29 (37%)	3 (38%)	3 (50%)
Unknown	170	16	14
CD4 at fully vaccinated	498 (305,746)	352 (172,542)	352 (291,423)
Unknown	181	18	16
Supressed HIV RNA at fully vaccinated	59 (87%)	5 (83%)	4 (100%)
Unknown	181	18	16

n(%); median (IQR)

Supplement Figure 4: Outcomes of breakthrough illness among those hospitalized after fully vaccinated to Dec 31, 2021, by HIV status (n=170 PWoH) and CD4 count (n=23 <350 cells/mm³ and n=45 \geq 350 cells/mm³) among PWH

